Clinical Trial

Study SC-101 in Subjects With Advanced Malignancies

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated July 29, 2025 (before its estimated March 2026 completion). Its status may not reflect the trial's current state.
Summary
This study will evaluate the safety, pharmacokinetics, and anti-cancer efficacy of SC-101 in subjects with advanced or metastatic solid tumors.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2024-01-23; most recent amendment 2025-07-28.
Status change: Not Yet Recruiting → Recruiting 2024-02-28
Trial Details
NCT Number NCT06220838
Lead Sponsor Tianjin ConjuStar Biologics Co., Ltd.
Conditions Advanced Solid Tumor
Enrollment 100 participants
Start Date 2024-02-02
Primary Completion 2026-03 (estimated)
Study Completion 2026-09 (estimated)
Updated on ClinicalTrials.gov 2025-07-29